HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Dec. 5, 2005--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce today that the third interim safety analysis of its ongoing multi-center Phase 2 trial of NX-1207 has revealed no serious drug side effects. NX-1207 is Nymox’s lead drug candidate for the treatment of benign prostatic hyperplasia (BPH) which the company believes shows good promise as a potential first-line treatment for BPH. In the two previously completed trials in the U.S., the drug has shown excellent efficacy without serious side effects.